



BRIGHT MINDS BIOSCIENCES FILES AMENDED Q1 INTERIM FINANCIAL STATEMENTS

Vancouver, British Columbia, March 8, 2021– Bright Minds Biosciences Inc. (CSE:DRUG) (“Bright Minds” or the “Company”) announces it has refiled its interim financial statements for the three months ended December 31, 2020 (the “**Amended Filings**”).

The Amended Filings were prepared following a review of the financial statements by the auditor for the Company. As a result of the interim review, the Amended Filings have been revised to:

- update Condensed Interim Consolidated Statements of Financial Position,
- update the Condensed Interim Consolidated Statements of Comprehensive Loss,
- update the Condensed Interim Consolidated Statements of Changes in Shareholders’ Equity,
- update the Condensed Interim Consolidated Statements of Cash Flows, and
- update the Notes to the Condensed Interim Consolidated Financial Statements.

The Amended Filings are available under the Company’s profile on SEDAR at www.sedar.com.

About Bright Minds

Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain. Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. The Company is developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.

Investor Contact:

Judy DiClemente

jdiclemente@insitecony.com